Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS), an intractable abacterial inflammatory disorder, affects 2%-10% men in the world (Sahin et al., 2015). Clinically, this type of prostatitis is generally defined as chronic pain in the prostatic region (that lasts for at least 3-6 months) (Schaeffer, 2006). Symptoms of CP/CPPS include voiding dysfunction, sexual complaints and chronic pain in the perineal, lower back and suprapubic regions (Zimmermann et al., 2009). CP/CPPS patients experience a deteriorated quality of life that is comparable to those suffered from angina pectoris or Crohn's disease (McNaughton Collins et al., 2001). To date, the complicated and heterogeneous pathophysiology of CP/CPPS has not yet been completely elucidated. Thus, the management of CP/CPPS is still one of the most challenging tasks in clinical practice (Marszalek et al., 2009). A variety of therapeutic approaches have been administrated individually and in various combinations, including analgesics, antiphlogistics, antibiotics and a-receptor blockers, the efficacy is far from satisfactory for patients (Qin et al., 2018). What is worse, side effects from these drugs, such